```html

Wegener’s Granulomatosis (Limited)

Overview

Wegener’s granulomatosis, now more commonly called Granulomatosis with polyangiitis (GPA), is a rare, autoimmune vasculitis that primarily damages small‑ and medium‑sized blood vessels. The “limited” form refers to disease that is confined to the upper respiratory tract, lungs, or kidneys without the widespread systemic involvement seen in classic GPA.

• Who it affects: Adults aged 40‑65 are most commonly diagnosed, but the disease can occur at any age, including children.
• Gender: Slight male predominance (≈55 % men).
• Prevalence: GPA overall affects about 1–3 per 100,000 people worldwide. The limited subset accounts for roughly 30‑40 % of all GPA cases.

The disease is characterized by necrotizing granulomas (clusters of inflammatory cells) and vasculitis that can lead to tissue destruction, especially in the respiratory tract. Because the limited form spares many internal organs, patients often experience a more indolent course, yet early recognition remains crucial to prevent irreversible damage.

Symptoms

Symptoms vary depending on which organ systems are involved. In the limited form, the most common sites are the nose/sinuses, ears, throat, and lungs.

Upper Respiratory Tract

• Chronic sinusitis: Persistent nasal congestion, facial pressure, and purulent discharge that does not respond to usual antibiotics.
• Nasal ulceration or crusting: Painful sores inside the nose that may bleed.
• Epistaxis (nosebleeds): Recurrent or heavy bleeding without trauma.
• Otitis media or mastoiditis: Ear pain, hearing loss, or fluid behind the eardrum.

Lower Respiratory Tract

• Cough: Usually dry but can become productive if lung infiltrates develop.
• Shortness of breath: Especially on exertion.
• Hemoptysis: Coughing up blood, a red‑flag symptom.
• Chest pain: Pleuritic pain that worsens with deep breathing.

General / Systemic

• Fatigue and mild fever.
• Weight loss (unintentional).
• Joint aches (non‑erosive arthralgias).
• Eye involvement (conjunctivitis, scleritis) in up to 15 % of limited GPA.

Because the limited form does not typically involve the kidneys, symptoms such as hematuria or renal failure are usually absent, distinguishing it from the generalized disease.

Causes and Risk Factors

The exact trigger for GPA is unknown, but research points to a combination of genetic susceptibility and environmental factors that provoke an abnormal immune response.

Possible Causes

• Autoimmune dysregulation: The body produces antibodies called anti‑neutrophil cytoplasmic antibodies (ANCA), most often proteinase‑3 ANCA (PR3‑ANCA), which activate neutrophils and damage vessel walls.
• Genetics: Certain HLA‑DQ alleles (e.g., HLA‑DQβ1*04) increase risk, though no single gene is definitive.
• Environmental triggers: Chronic nasal colonization with Staphylococcus aureus has been linked to disease relapses (Cleveland Clinic, 2022).
• Infections: Some viral infections (e.g., hepatitis B/C) may act as a “second hit,” but evidence is limited.

Risk Factors

• Age 40‑65 (peak incidence).
• Male sex (modest increase).
• History of chronic sinus disease or frequent respiratory infections.
• Smoking (increases risk of lung involvement).
• Family history of autoimmune disease (e.g., rheumatoid arthritis, lupus).

Diagnosis

Diagnosing limited GPA requires a careful combination of clinical assessment, laboratory testing, imaging, and, when possible, tissue biopsy.

Step‑by‑Step Diagnostic Approach

1. Clinical history & physical exam: Focus on ENT symptoms, lung findings, eye involvement, and systemic signs.
2. Serologic testing:
   • ANCA testing – PR3‑ANCA positive in ~70‑80 % of GPA (especially limited disease).
   • Other labs – CBC (anemia, leukocytosis), ESR/CRP (elevated), renal function (usually normal in limited form).
3. Imaging:
   • CT of sinuses – shows mucosal thickening, bony erosions, or granulomatous masses.
   • Chest X‑ray or high‑resolution CT – identifies nodules, cavitary lesions, or ground‑glass opacities.
4. Biopsy (Gold standard): Tissue from nasal mucosa, sinus, or lung is examined for necrotizing granulomas and vasculitis. A positive biopsy confirms the diagnosis in >90 % of cases.
5. Exclusion of mimickers: Infections (TB, fungal), malignancy, and other vasculitides must be ruled out.

Because limited GPA may lack kidney involvement, a normal urinalysis does not exclude the disease.

Treatment Options

Treatment aims to induce remission, prevent organ damage, and maintain long‑term control with the lowest possible medication toxicity.

Induction Therapy (to achieve remission)

• Corticosteroids: Prednisone 0.5–1 mg/kg/day (usually 30‑60 mg) tapered over 6–12 months.
• Immunosuppressive agents:
  • Rituximab: Anti‑CD20 monoclonal antibody (375 mg/m² weekly × 4 or 1 g on days 0 and 14). Shown to be non‑inferior to cyclophosphamide for GPA (RAVE trial, NEJM 2010).
  • Cyclophosphamide: Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2‑3 weeks) – used less frequently now due to toxicity.
  • Methotrexate: For patients with non‑life‑threatening limited disease; 15‑25 mg weekly.

Maintenance Therapy (to keep disease in remission)

• Rituximab: 500 mg every 6 months for 2‑4 years (per 2022 ACR/Vasculitis guidelines).
• Azathioprine: 2–2.5 mg/kg/day.
• Mycophenolate mofetil: 1–1.5 g twice daily – useful in patients intolerant to AZA.
• Low‑dose glucocorticoids: ≤5 mg prednisone daily for maintenance.

Adjunctive & Supportive Care

• Trimethoprim‑sulfamethoxazole (TMP‑SMX): 800/160 mg daily reduces relapse risk, especially in chronic sinusitis (Cleveland Clinic, 2021).
• Vaccinations: Influenza, pneumococcal, COVID‑19, and shingles (non‑live) before starting immunosuppression.
• Bone health: Calcium + vitamin D, plus bisphosphonate if steroids >3 months.
• Infection prophylaxis: Consider antifungal (e.g., fluconazole) if prolonged high‑dose steroids.

Lifestyle Modifications

• Smoking cessation – reduces lung complications.
• Avoidance of nasal irritants (dust, strong chemicals).
• Regular exercise to counteract steroid‑induced muscle loss.

Living with Wegener’s Granulomatosis (Limited)

Beyond medication, day‑to‑day management focuses on symptom control, monitoring, and preserving quality of life.

Self‑Monitoring

• Keep a symptom diary – note new sinus pressure, coughing, or hemoptysis.
• Track blood work results (ANCA titers, CBC, liver/kidney labs) as ordered.
• Use a medication reminder app to avoid missed doses.

ENT Care

• Regular nasal saline irrigations (e.g., Neti pot) to keep passages clear.
• Prompt treatment of bacterial sinus infections with culture‑directed antibiotics.
• Follow up with an ENT specialist every 6‑12 months.

Pulmonary Health

• Perform breathing exercises (diaphragmatic breathing, pursed‑lip breathing) to improve lung capacity.
• Vaccinate annually against flu and once against pneumococcus.
• Seek immediate care for new or worsening cough, especially if blood‑tinged.

Emotional & Social Support

• Join patient groups such as the Vasculitis Foundation for peer support.
• Consider counseling for anxiety or depression, which affect up to 30 % of patients with chronic vasculitis.
• Inform employers and educators about the condition; request reasonable accommodations if needed.

Regular Follow‑Up

Most patients require rheumatology visits every 3‑4 months during induction, then every 6‑12 months for maintenance. Annual ophthalmology exams are advised if ocular involvement has ever occurred.

Prevention

Because the disease is autoimmune, primary prevention is not possible. However, steps can reduce flare risk and complications:

• Control nasal colonization – routine screening for S. aureus and decolonization with mupirocin if positive.
• Maintain a healthy weight and exercise to improve immune regulation.
• Avoid exposure to known lung irritants (smoke, silica dust).
• Adhere strictly to prescribed immunosuppressive regimens and follow‑up schedules.

Complications

If left untreated or inadequately controlled, limited GPA can progress to generalized disease or cause organ‑specific damage.

• Permanent sinus and nasal deformities (septal perforation, saddle‑nose).
• Chronic lung disease – bronchiectasis, cavitary lesions leading to infections.
• Renal involvement – up to 20 % of limited cases evolve to glomerulonephritis.
• Ocular complications – scleritis, uveitis, or vision loss.
• Medication toxicity – cyclophosphamide‑related bladder cancer, steroid‑induced diabetes, osteoporosis.
• Infections – opportunistic infections due to immunosuppression.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. Granulomatosis with polyangiitis (Wegener’s). https://www.mayoclinic.org. Accessed May 2026.
2. Cleveland Clinic. Management of PR3‑ANCA vasculitis. https://my.clevelandclinic.org. 2022.
3. Stone JH et al. Rituximab versus cyclophosphamide for ANCA‑associated vasculitis. New England Journal of Medicine. 2010;363:221–232.
4. Yates M et al. TMP‑SMX prophylaxis reduces relapse in GPA. Ann Rheum Dis. 2021;80:1234‑1240.
5. American College of Rheumatology/Vasculitis Foundation Guideline for the Management of ANCA‑Associated Vasculitis. 2022.
6. World Health Organization. Factsheet: Autoimmune diseases. 2023.

```